secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001077183-23-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q1 revenue up 17% to $137M; narrows net loss; raises FY2023 guidance
--------------------------------------------------------------------------------

- Consolidated revenue $137M (+17% YoY); Clinical +16% to $115M, Pharma +22% to $22M.
- Net loss improved to $31M from $49M; Adjusted EBITDA loss narrowed to $7M from $19M.
- FY2023 revenue guidance raised to $555-$565M from $545-$555M; Adj. EBITDA loss guidance improved to $(22)-$(18)M.
- Cash and marketable securities $418M; adjusted gross profit margin 43.5%.
- Clinical test volume +7% YoY; revenue per test +8% to $402.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718323000039/0001077183-23-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718323000039/neo-20230508.htm
  HTML page:      https://secwatch.observer/filing/0001077183-23-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer